Compare GCTS & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | STRO |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.8M | 159.5M |
| IPO Year | 2021 | 2018 |
| Metric | GCTS | STRO |
|---|---|---|
| Price | $1.11 | $8.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $3.13 | ★ $44.69 |
| AVG Volume (30 Days) | ★ 1.7M | 291.0K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,866,000.00 | ★ $38,419,000.00 |
| Revenue This Year | $76.29 | N/A |
| Revenue Next Year | $648.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.96 | $0.72 |
| 52 Week High | $3.93 | $43.85 |
| Indicator | GCTS | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 35.40 |
| Support Level | $1.00 | $8.11 |
| Resistance Level | $1.43 | $10.77 |
| Average True Range (ATR) | 0.15 | 0.85 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 23.83 | 17.01 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.